Russell Starr Appointed President of Vector Science & Therapeutics
Russell Starr has been appointed President of Vector Science & Therapeutics Corp. Starr is a capital markets executive and long-time stakeholder of the company.
Vector Science & Therapeutics Corp. announced on October 14, 2026, the appointment of Russell Starr as President, effective October 5, 2026. Starr, a capital markets executive and existing stakeholder, will receive his salary in company shares, signaling a commitment to future growth. Bill Jackson will continue as Chief Executive Officer.
As part of his appointment, Starr was granted 1,500,000 stock options with a five-year term, subject to vesting based on specific stock price targets. These performance-based incentives are designed to align his interests with long-term shareholder value.
Starr brings extensive experience in corporate finance, strategic transactions, and driving growth for public companies, having raised over $2 billion in equity financing. He has held senior roles across multiple public companies, focusing on capital formation and corporate development. Vector Science & Therapeutics is developing pharma-grade peptides and non-opioid solutions for pain management, along with novel drug delivery systems.
Tommy Thompson, Chairman of Vector Science & Therapeutics, stated Starr's judgment and experience are crucial for the company's next phase. CEO Bill Jackson highlighted Starr's role in the company's current initiatives. Starr expressed his honor in taking the role at a pivotal moment for the company, particularly with the production of pharma-grade peptides.
Vector Science & Therapeutics is a medical technology company headquartered in Mequon, Wisconsin, focused on drug delivery and peptide manufacturing for sports medicine, regenerative medicine, and pain management markets.